(2R,4R)-叔丁基 4-羟基-2-(羟基甲基)吡咯烷-1-羧酸 | 141850-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (2R,4R)-叔丁基 4-羟基-2-(羟基甲基)吡咯烷-1-羧酸
• 中文别名: (2R,4R)-4-羟基-2-(羟甲基)-1-吡咯烷羧酸叔丁酯；(2R,4R)-叔丁基4-羟基-2-(羟基甲基)吡咯烷-1-羧酸
• 英文名称: (2R,4R)-tert-butyl 4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate
• 英文别名: tert-butyl (2R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate；(2R,4R)-4-hydroxyprolinol-1-carboxylic acid tert-butyl ester；(2R,4R)-N-Boc-4-hydroxyprolinol；(2R,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester；(2R,4R)-4-hydroxy-2-hydroxymethylpyrrolidine-1-carboxylic acid tert-butyl ester；1,1-dimethylethyl (2R,4R)-4-hydroxy-2-(hydroxymethyl)-1-pyrrolidinecarboxylate
• CAS: 141850-54-6
• 化学式: C₁₀H₁₉NO₄
• 分子量: 217.265
• InChiKey: UFJNFQNQLMGUTQ-HTQZYQBOSA-N

物化性质

• 密度：
  1.190

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-BOC-(2R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidine
Synonyms: tert-Butyl (2R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-BOC-(2R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidine
CAS number: 141850-54-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H19NO4
Molecular weight: 217.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2R,4R)-叔丁基 4-羟基-2-(羟基甲基)吡咯烷-1-羧酸 在 咪唑 、 叔丁基二苯基氯硅烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以41%的产率得到tert-butyl (2R,4R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-4-hydroxypyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] PYRROLIDINE GPR40 MODULATORS
  [FR] MODULATEURS PYRROLIDINES DE GPR40

  摘要：

  本发明提供了式(I)的化合物：或其立体异构体，或其药物可接受的盐，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。

  公开号：

  WO2014078609A1
• 作为产物：
  描述：

  顺式-4-羟基-D-脯氨酸甲酯 在 锂硼氢 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 4.0h， 生成 (2R,4R)-叔丁基 4-羟基-2-(羟基甲基)吡咯烷-1-羧酸
  参考文献：
  名称：

  Accessible Chiral Linker to Enhance Potency and Selectivity of Neuronal Nitric Oxide Synthase Inhibitors

  摘要：

  The three important mammalian isozymes of nitric oxide synthase (NOS) are neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). Inhibitors of nNOS show promise as treatments for neurodegenerative diseases. Eight easily synthesized compounds containing either one (20a,b) or two (9a-d; 15a,b) 2-amino-4-methylpyridine groups with a chiral pyrrolidine linker were designed as selective nNOS inhibitors. Inhibitor 9c is the best of these compounds, having a potency of 9.7 nM and dual selectivity of 693 and 295 against eNOS and iNOS, respectively. Crystal structures of nNOS complexed with either 9a or 9c show a double-headed binding mode, where each 2-aminopyridine headgroup interacts with either a nNOS active site Glu residue or a heme propionate. In addition, the pyrrolidine nitrogen of 9c contributes additional hydrogen bonds to the heme propionate, resulting in a unique binding orientation. In contrast, the lack of hydrogen bonds from the pyrrolidine of 9a to the heme propionate allows the inhibitor to adopt two different binding orientations. Both 9a and 9c bind to eNOS in a single-headed mode, which is the structural basis for the isozyme selectivity.

  DOI：

  10.1021/ml400381s

文献信息

• [EN] SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY<br/>[FR] COMPOSÉS DE SULFONAMIDE AYANT UNE ACTIVITÉ INHIBITRICE DE TNAP
  申请人：DAIICHI SANKYO CO LTD

  公开号：WO2018119444A1

  公开（公告）日：2018-06-28

  The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有优异的组织非特异性碱性磷酸酶抑制活性的化合物或其药理学上可接受的盐。本发明提供一种由式(I)表示的化合物或其药理学上可接受的盐。
• Thiophene-2-carboximidamide Based Selective Neuronal Nitric Oxide Inhibitors
  申请人：Silverman Richard B.

  公开号：US20140066635A1

  公开（公告）日：2014-03-06

  Selective neuronal nitric oxide synthase (nNOS) inhibitor compounds designed with one or more thiophene-2-carboximidamide substituents for improved bioavailability.

  选择性神经型一氧化氮合酶（nNOS）抑制剂化合物设计为具有一个或多个噻吩-2-羧酰胺取代基，以提高生物利用度。
• [EN] PYRROLIDINE GPR40 MODULATORS<br/>[FR] MODULATEURS DE GPR40 À BASE DE PYRROLIDINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015171757A1

  公开（公告）日：2015-11-12

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体、药用盐、多晶型或溶剂化物，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。
• [EN] PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES<br/>[FR] COMPOSÉS PYRROLIDINE MODULATEURS DE GPR40 POUR LE TRAITEMENT DE MALADIES TELLES QUE LE DIABÈTE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015171722A1

  公开（公告）日：2015-11-12

  The present invention provides compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式（I）的化合物或其立体异构体、互变异构体、药学上可接受的盐、多型体或溶剂化合物，其中所有变量均如本文所定义。这些化合物是GPR40 G蛋白偶联受体调节剂，可用作药物。
• Design, Synthesis, and Antileukemic Activity of Stereochemically Defined Constrained Analogues of FTY720 (Gilenya)
  作者：Rebecca Fransson、Alison N. McCracken、Bin Chen、Ryan J. McMonigle、Aimee L. Edinger、Stephen Hanessian

  DOI：10.1021/ml4002425

  日期：2013.10.10

  sphingosine-1-phosphate receptors. At doses well above those needed for immunosuppression, FTY720 also has antineoplastic actions. Our published work suggests that at least some of FTY720’s anticancer activity is independent of its effects on S1P receptors and due instead to its ability to induce nutrient transporter down-regulation. Compounds that trigger nutrient transporter loss but lack FTY720’s S1P

  FTY720 由于其对 1-磷酸鞘氨醇受体的影响而起到免疫抑制剂的作用。在远高于免疫抑制所需的剂量下，FTY720 还具有抗肿瘤作用。我们已发表的工作表明，至少 FTY720 的某些抗癌活性与其对 S1P 受体的影响无关，而是由于其诱导营养转运蛋白下调的能力。引发营养转运蛋白损失但缺乏 FTY720 的 S1P 受体相关、剂量限制性毒性的化合物有可能成为有效和选择性的抗肿瘤剂。在这项研究中，一系列对映异构纯和立体化学多样化的O生成吡咯烷的-取代苄基醚并测试其杀死人类白血病细胞的能力。发现羟甲基的​​立体化学是化合物活性的关键决定因素。此外，抗白血病活性不需要该基团的磷酸化。